Publication
Mutant HRAS as novel target for MEK and mTOR inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerMalignant Neoplasmcivic_curation1.00
- drugBinimetinibcivic_curation1.00
- drugEverolimuscivic_curation1.00
- drugMirdametinibcivic_curation1.00
- drugMTOR Kinase Inhibitor AZD8055civic_curation1.00
- drugSelumetinibcivic_curation1.00
- geneHRAScivic_curation1.00
- variantHRAS G12Vcivic_curation1.00
- variantHRAS Q61Lcivic_curation1.00
- variantHRAS Q61Rcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26544513
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| HRAS Q61L1 | ||||||||
| Everolimus + SelumetinibCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID1955Inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Cells transformed with mutant HRAS isoforms Q61L, Q61R and G12V demonstrated equal sensitivity to… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC | civic |
| HRAS G12V + HRAS Q61L + HRAS Q61R1 | ||||||||
| Binimetinib + Everolimus + Mirdametinib + MTOR Kinase Inhibitor AZD8055 + SelumetinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID700In preclinical cancer cell line and Ba/F3 models, HRAS Q61L, Q61R, and G12V mutations conferred sensitivity to MEK inhibitors (AZD6244/selumetinib, MEK162/binimetinib, and PD0325901) and mTOR inhibito… (full text at CIViC) PMID 26544513 · Kiessling et al., 2015 · Open in CIViC | civic |